Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
K
Kopran Ltd
Score 48/100• Risky
Kopran Ltd operates in a promising sector but faces significant challenges in growth consistency and market sentiment, making it a risky investment at this time.
Company’s Health73/100
Valuation 80/100 · PB 1.5405
Technical Avoid
1M -4.921% 6M -13.036% 1Y -42.41%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#226
View details ➜
K
KOBO Biotech Ltd
Score 48/100• Risky
KOBO Biotech Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
Company’s Health41/100
Valuation 100/100 · PB -0.0525
Technical Avoid
1M 30.396% 6M 3.333% 1Y 5.085%
Confidence100%
No promoter pledgeReasonable PB valuation
Thin margins
#227
View details ➜
K
Kimia Biosciences Ltd
Score 48/100• Risky
Kimia Biosciences Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health56/100
Valuation 20/100 · PB 15.0251
Technical Avoid
1M -10.528% 6M -18.311% 1Y -35.118%
Confidence100%
No promoter pledgeDecent revenue growth
High debt/equityThin margins
#228
View details ➜
K
Kabra Drugs Ltd
Score 48/100• Risky
Kabra Drugs Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in performance metrics.
Company’s Health60/100
Valuation 80/100 · PB 1.7267
Technical Avoid
1M -3.155% 6M 62.094% 1Y 96.499%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#229
View details ➜
I
Ishita Drugs and Industries Ltd
Score 48/100• Risky
Ishita Drugs and Industries Ltd presents a risky investment profile with inconsistent growth and moderate profitability metrics. Caution is advised.
Company’s Health59/100
Valuation 60/100 · PB 2.0231
Technical Avoid
1M -7.75% 6M -3.833% 1Y -3.859%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#230
View details ➜
F
Fortis Malar Hospitals Ltd
Score 48/100• Decent
Fortis Malar Hospitals Ltd shows potential in a growing sector but faces challenges in profitability and market sentiment.
Company’s Health52/100
Valuation 40/100 · PB 4.1349
Technical Avoid
1M 4.156% 6M -12.75% 1Y 22.631%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#231
View details ➜
C
Chandra Bhagat Pharma Ltd
Score 48/100• Risky
Chandra Bhagat Pharma Ltd presents a mixed outlook with several risks overshadowing its potential growth. Caution is advised for investors.
Company’s Health51/100
Valuation 80/100 · PB 1.0825
Technical Avoid
1M 10.836% 6M -31.467% 1Y -42.076%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#232
View details ➜
C
Chandan Healthcare Ltd
Score 48/100• Risky
Chandan Healthcare Ltd shows potential in a growing sector, but faces significant risks in terms of growth consistency and market valuation.
Company’s Health93/100
Valuation 20/100 · PB 6.3065
Technical Momentum
1M 46.861% 6M 76.169% 1Y 88.059%
Confidence100%
Low leverage (D/E)No promoter pledge
#233
View details ➜
C
Cell Point (India) Ltd
Score 48/100• Risky
Cell Point (India) Ltd shows potential but faces significant challenges in growth and profitability, making it a risky investment at this time.
Company’s Health57/100
Valuation 100/100 · PB 0.4517
Technical Avoid
1M -8.533% 6M 4.058% 1Y -44.513%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#234
View details ➜
B
Bal Pharma Ltd
Score 48/100• Decent
Bal Pharma Ltd shows potential but faces significant challenges in growth and market sentiment.
Company’s Health57/100
Valuation 80/100 · PB 1.6957
Technical Avoid
1M -0.755% 6M -18.326% 1Y -33.497%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEHigh debt/equity
#235
View details ➜
J
Johnson Pharmacare Ltd
Score 48/100• Risky
Johnson Pharmacare Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health50/100
Valuation 100/100 · PB 0.754
Technical Avoid
1M -2.564% 6M -18.947% 1Y -31.25%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#236
View details ➜
G
GPT Healthcare Ltd
Score 48/100• Decent
GPT Healthcare Ltd shows potential but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
Company’s Health93/100
Valuation 40/100 · PB 4.921
Technical Avoid
1M 1.209% 6M -3.78% 1Y -13.132%
Confidence100%
Low leverage (D/E)No promoter pledge
#237
View details ➜
G
Genpharmasec Ltd
Score 48/100• Risky
Genpharmasec Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health63/100
Valuation 80/100 · PB 1.3656
Technical Avoid
1M -12.105% 6M -20.69% 1Y -48.889%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#238
View details ➜
E
Evexia Lifecare Ltd
Score 48/100• Decent
Evexia Lifecare Ltd shows potential in a growing sector but faces challenges in profitability and market sentiment.
Company’s Health22/100
Valuation 60/100 · PB 2.6122
Technical Avoid
1M -13.171% 6M -33.333% 1Y -55.774%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEHigh debt/equity
#239
View details ➜
C
Colinz Laboratories Ltd
Score 48/100• Decent
Colinz Laboratories Ltd shows decent potential with consistent growth and profitability metrics, but faces challenges in market sentiment and execution risks.
Company’s Health60/100
Valuation 80/100 · PB 1.1036
Technical Avoid
1M 1.806% 6M -16.084% 1Y -33.027%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#240
View details ➜
Showing 226 to 240 of 301 (21 Pages)